SCHEMBL1362427

SCHEMBL1362427

CC(C)c1cccc(C(C)C)c1OC(=O)Cl

nearest known ligand 0.69

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 1/20 0.48
SCN9A Q15858 1/20 0.48
SCN10A Q9Y5Y9 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1952758 0.83 SCN5A (0.58) SCN5ASCN9ASCN10A
Chloromethane SCHEMBL28360619 0.82 SCN5A (0.47) SCN5ASCN9ASCN10A
SCHEMBL11138205 0.82 SCN5A (0.33) SCN5ASCN9ASCN10A
SCHEMBL1927023 0.82 SCN5A (0.49) SCN5ASCN9ASCN10A
SCHEMBL4023092 0.82 SCN5A (0.49) SCN5ASCN9ASCN10A
SCHEMBL2016482 0.80 SCN5A (0.48) SCN5ASCN9ASCN10A
SCHEMBL23277004 0.79 SMN1; SMN2 (0.51) SCN5ASCN9ASCN10A
SCHEMBL11225641 0.79 SCN5A (0.44) SCN5ASCN9ASCN10A
SCHEMBL5836784 0.78 CYP1A2 (0.48)
SCHEMBL6946542 0.78 SCN5A (0.47) SCN5ASCN9ASCN10A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109400645-A A kind of phosphoric acid derivatives and preparation method and purposes 四川海思科制药有限公司 2019-03-01 CN disclosed
US-9023813-B2 Synthesis and use of glycoside derivatives of propofol NuTek Pharma Ltd. (US) 2015-05-05 US disclosed
US-20120295866-A1 Synthesis And Use Of Glycoside Pro-Drug Analogs NuTek Pharma Ltd. 2012-11-22 US disclosed
US-20120264702-A1 Synthesis And Use Of Glycoside Derivatives of Propofol NuTek Pharma Ltd. 2012-10-18 US disclosed
US-8067455-B2 Amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof XENOPORT, INC. (US) 2011-11-29 US disclosed
US-8067455-B2 Amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof XENOPORT, INC. (US) 2011-11-29 US disclosed
US-8067455-B2 Amino acid derived prodrugs of propofol, compositions, uses and crystalline forms thereof XENOPORT, INC. (US) 2011-11-29 US disclosed
US-20100087536-A1 AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS, USES AND CRYSTALLINE FORMS THEREOF XENOPORT, INC. (US) 2010-04-08 US disclosed
US-20100087536-A1 AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS, USES AND CRYSTALLINE FORMS THEREOF XENOPORT, INC. (US) 2010-04-08 US disclosed
US-20100087536-A1 AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS, USES AND CRYSTALLINE FORMS THEREOF XENOPORT, INC. (US) 2010-04-08 US disclosed
US-5981595-A LOWERS BLOOD CHOLESTEROL LEVELS WARNER-LAMBERT COMPANY (US) 1999-11-09 US disclosed
US-5846942-A Cholecystokinin antagonists, their preparation and therapeutic use WARNER-LAMBERT COMPANY (US) 1998-12-08 US disclosed
US-5593967-A Cholecystokinin antagonists, their preparation and therapeutic use WARNER-LAMBERT COMPANY (US) 1997-01-14 US disclosed
EP-0547178-A4 NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE WARNER LAMBERT CO (US) 1994-07-06 EP disclosed
US-5254589-A Anticholesterol agent WARNER-LAMBERT COMPANY (US) 1993-10-19 US disclosed
EP-0547178-A1 NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE WARNER-LAMBERT COMPANY (US) 1993-06-23 EP disclosed
WO-1993008161-A1 SULFONYL UREA AND CARBAMATE ACAT INHIBITORS WARNER-LAMBERT COMPANY (US) 1993-04-29 WO disclosed
WO-1992004045-A1 NOVEL CHOLECYSTOKININ ANTAGONISTS, THEIR PREPARATION AND THERAPEUTIC USE WARNER-LAMBERT COMPANY (US) 1992-03-19 WO disclosed
US-5087726-A Carbamate ACAT inhibitors WARNER-LAMBERT COMPANY (US) 1992-02-11 US disclosed
US-4751173-A USING QUATERNARY COMPOUND; RAPID, SELECTIVE FUJI PHOTO FILM CO., LTD. (JP) 1988-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120295866-A1 Synthesis And Use Of Glycoside Pro-Drug Analogs GCG, CYP3A5, UGT1A6 SCN5A 1423/4885SCN9A 3539/4885SCN10A 2714/4885
US-20100087536-A1 AMINO ACID DERIVED PRODRUGS OF PROPOFOL, COMPOSITIONS, USES AND CRYSTALLINE FORMS THEREOF PELP1, CYP3A5, CYP2C19 SCN5A 254/4885SCN9A 677/4885SCN10A 634/4885
US-20120264702-A1 Synthesis And Use Of Glycoside Derivatives of Propofol CYP3A5, CYP3A4, UGT1A4 SCN5A 529/4885SCN9A 2695/4885SCN10A 1554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.